AVPR1B Antikörper (AA 23-120) (Alexa Fluor 555)

Produktnummer ABIN1393397

Produktdetails anti-AVPR1B Antikörper (Alexa Fluor 555)

Target: AVPR1B (Arginine Vasopressin Receptor 1B (AVPR1B))

Bindungsspezifität: AA 23-120

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AVPR1B Antikörper ist konjugiert mit Alexa Fluor 555

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Homologie: Human,Mouse,Rat,Dog,Cow,Pig,Horse

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human AVP Receptor V3

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu AVPR1B

Target: AVPR1B (Arginine Vasopressin Receptor 1B (AVPR1B))

Andere Bezeichnung: AVPR1B/AVP Receptor V3 (AVPR1B Produkte)

Synonyme: LOC443050 antikoerper, AVPR1B antikoerper, si:ch211-125a15.3 antikoerper, AVPR3 antikoerper, V3/V1b antikoerper, VIBR antikoerper, VPR3 antikoerper, arginine vasopressin receptor 1B antikoerper, arginine vasopressin receptor 1Ab antikoerper, AVPR1B antikoerper, avpr1ab antikoerper, Avpr1b antikoerper

Hintergrund:

Synonyms: Antidiuretic hormone receptor 1b, Arginine vasopressin receptor 1B, Arginine vasopressin receptor 3, AVPR V1b, AVPR V3, Avpr1b, AVPR3, Pituitary vasopressin receptor 3, V1bR, V1BR_HUMAN, Vasopressin V1b receptor, Vasopressin V3 receptor, VPR3.

Background: Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3). AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2). The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3). It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4). The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3). The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6). Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7). The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7). The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8). AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2).

Pathways: Regulation of Systemic Arterial Blood Pressure by Hormones